Discussion
Gene therapy to restore activity of the defective NaV1.1 protein in a specific region of the brain — the hippocampus — is sufficient to reduce seizure risk in Dravet syndrome, according to a mouse study. The findings indicate that seizure risk may be further reduced with gene therapy that…